

1 **Effectiveness of BNT162b2 and ChAdOx1 vaccines against symptomatic COVID-19 among**
2 **Healthcare Workers in Kuwait: A retrospective cohort study**

3 Walid Q. Alali^{1*}, Lamiaa A. Ali², Mohammad AlSeaidan³, Mohammad Al-Rashidi⁴

4 ¹ Department of Epidemiology & Biostatistics, Faculty of Public Health, Kuwait University,
5 Safat, Kuwait

6 ² Quality and accreditation directorate, Farwania Hospital, Farwania, Kuwait

7 ³ Department of Public Health, Ministry of Health, Kuwait City, Kuwait

8 ⁴ Hospital Administration, Farwania Hospital, Farwania, Kuwait

9

10

11 *Corresponding author:

12 Walid Q. Alali

13 Department of Epidemiology and Biostatistics

14 Faculty of Public Health

15 Kuwait University

16 Safat, Kuwait

17 w.alali@ku.edu.kw

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

Abstract

Background: The COVID-19 BNT162b2 vaccination roll-out in Kuwait started on 24 December 2020 followed by ChAdOx1 on 3 February 2021. The study objectives were to assess the factors associated with vaccine coverage and determine vaccine effectiveness (VE) against SARS-CoV-2 infection in a healthcare worker (HCW) population.

Methods: This retrospective cohort study was conducted among HCW working at a public secondary hospital in Kuwait. The follow-up period was from 24 December 2020 to 15 June 2021. The primary outcomes were vaccine coverage and PCR-confirmed SARS-CoV-2 infection for the VE analysis. Data on new SARS-CoV-2 infections (with or without symptoms) during study period in addition to HCWs characteristics (sex, age, nationality, and occupation) were extracted from the hospital records. The vaccine coverage and PCR-confirmed SARS-CoV-2 infections were cross-tabulated by the HCWs characteristics. Furthermore, we used Cox regression to estimate time-to-infection hazard ratios in vaccinated (first and second dose) compared to unvaccinated HCWs. Only one ChAdOx1 dose was given during the study period.

Results: There were 3246 HCWs included in the analysis. The median age was 38 years (IQR = 33 - 44), 63.4% were females, 46.8% aged 31-40, and 82.3% were non-Kuwaitis. Overall, 82.1% of HCWs received at least one vaccine dose (50.4% received only one dose of ChAdOx1, 3.3% received one dose of BNT162b2, and 28.3% received two doses of BNT162b2). 17.9% of HCWs remained unvaccinated by the end of the study. A significantly lower vaccination coverage percentage was amongst female HCWs, younger age group (20 – 30 years old), and administrative/executive staff. Symptomatic SARS-CoV-2 PCR-confirmed infection prevalence was 7.3%. No asymptomatic infections were reported. The SARS-CoV-2 infection incidence rate was 126 per 100,000 person-days in the unvaccinated group; whereas, the incidence rates in the

41 partially vaccinated groups (≥ 28 days after ChAdOx1 first dose) and (≥ 14 days after receiving
42 BNT162b2 through receipt of second dose) were 31.4 and 10.9 per 100,000 person-days,
43 respectively. In the fully vaccinated group (≥ 14 days after BNT162b2 second dose), the
44 incidence rate was 6.3 per 100,000 person-days. The estimated adjusted vaccine effectiveness of
45 fully vaccinated was 94.5% (95% confidence interval [CI] = 89.4%–97.2%). The VE of partially
46 vaccinated for ChAdOx1 and BNT162b2 was 75.4% (95% CI = 67.2%–81.6%) and 91.4% (95%
47 CI = 65.1%–97.9%), respectively.

48 **Conclusions:** Both BNT162b2 and ChAdOx1 vaccines prevented most symptomatic infections
49 in this population across age groups, nationalities, and occupations. A significant proportion
50 (17.9%) of HCWs were unvaccinated despite the vaccine accessibility. The findings complement
51 other VE studies and demonstrate the vaccine benefit among HCWs.

52

53 **1. Introduction**

54 The two anti-COVID-19 vaccines (BNT162b2 mRNA [Pfizer-BioNTech] and ChAdOx1
55 nCoV-19 adenoviral [Oxford-AstraZeneca] have shown to be effective in preventing
56 asymptomatic/symptomatic COVID-19, hospitalization, and death based on both clinical trials
57 and population-level observational studies (Abu-Raddad, Chemaitelly, & Butt, 2021; Haas et al.,
58 2021; Hall et al., 2021; Polack et al., 2020; Vasileiou et al., 2021; Voysey et al., 2021). Both
59 vaccines have been authorized for use in Kuwait. Local BNT162b2 vaccination roll-out started
60 on 24th December 2020 followed by ChAdOx1 on 3rd February 2021.

61 COVID-19 vaccine effectiveness under ‘real-world’ conditions are important to conduct not
62 only in the general population but also in risk-specific groups such as healthcare workers
63 (HCWs) due to their higher exposure rates to SARS-CoV-2. It is well-known that HCWs come
64 in contact with patients directly and indirectly depending on their occupation. Therefore, they
65 considered high risk group for SARS-CoV-2 infection and consequently at risk for disease
66 complications. Recent studies have shown that vaccination reduce the rate of infection among
67 HCWs (Amit, Regev-Yochay, Afek, Kreiss, & Leshem, 2021; Hall et al., 2021; Moustsen-Helms
68 et al., 2021; Thompson et al., 2021). In the study from Israel, the incidence rate among
69 BNT162b2 vaccinated HCWs was 3 cases per 10,000 person-days compared to 7.4 cases per
70 10,000 person-day in unvaccinated (Amit et al., 2021). Moreover, a study from United Kingdom
71 (UK) revealed that in a single dose of BNT162b2 vaccine was 70% effective in reducing SARS-
72 CoV-2 infections among HCWs 21 days after first dose and 85% after 7 days post second dose
73 (Hall et al., 2021). Furthermore, a study from United States (US) on two mRNA vaccines
74 (BNT162b2 and Moderna mRNA-1273) among HCWs, full immunization (≥ 14 days after
75 second dose) was 90% effective against SARS-CoV-2 infections regardless of the symptom’s

76 status and 80% effectiveness in partially immunized (≥ 14 days after first dose but before second
77 dose).

78 While there are few studies that mostly evaluated impact of mRNA vaccines effectiveness in
79 HCWs population; there is limited data on mRNA and non-mRNA vaccine effectiveness in
80 HCWs population. Furthermore, there has been no published study on vaccine effectiveness
81 among HCWs in Gulf Cooperation Council countries and most of Middle Eastern countries.
82 Therefore, the objective of this retrospective cohort study was to assess the two vaccines
83 (BNT162b2 and ChAdOx1) effectiveness against symptomatic SARS-CoV-2 infection and in
84 relation to healthcare workers characteristics. We anticipate that the study findings will inform
85 HCWs across the country, the region, and internationally of the importance of vaccination
86 against COVID-19.

87 **2. Methods**

88 **2.1. Study design and study population**

89 The study was a retrospective cohort study among HCWs working at a public secondary
90 hospital in Kuwait. The hospital is a 900-bed facility with multiple medical and surgical
91 specialties including outpatient polyclinics. The original study population was 3673 HCWs (aged
92 ≥ 20 years) working at this hospital. The study started on 24th December 2020 (i.e., the day
93 vaccine roll-out began in Kuwait). HCWs with PCR-confirmed SARS-CoV-2 before the start of
94 the study were excluded. The study ended on 15th June 2021. The two cohorts we followed were
95 vaccinated and non-vaccinated HCWs. The main outcome of interest was symptomatic SARS-
96 CoV-2 PCR-confirmed infections.

97 The study was approved by the Ministry of Health Standing Committee for the
98 Coordination of Health and Medical Research (i.e., Ethics Committee), Kuwait City, Kuwait
99 (Approval number: 1666/2021).

100 **2.2. Data collection**

101 Vaccination data were obtained from the hospital records. The hospital administration
102 staff started collecting vaccination data on 10th January 2021 from all HCWs. They regularly
103 followed up with all hospital departments and requested specific vaccine-related data on HCWs
104 including vaccination status (vaccinated or unvaccinated); vaccination date (for first and second
105 dose); vaccine type (BNT162b2 or ChAdOx1); SARS-CoV-2 PCR-confirmed infections
106 (symptomatic or asymptomatic) and infection date. Additionally, sociodemographic (sex, age,
107 and nationality), occupation setting (e.g., outpatient, inpatient, intensive care), and staff
108 occupation (e.g., doctor, nurse, pharmacist) were available in the hospital records. The
109 sociodemographic and occupation data were matched with collected vaccination data using the
110 civil identification number of the HCWs. The HCW testing for SARS-CoV-2 was voluntary on
111 the basis of appearance of COVID-19 like symptoms or being a close-contact with COVID-19
112 positive case. A HCW was considered COVID-19 symptomatic if he/she had at least one typical
113 disease symptoms such as fever, cough, or change in taste or smell. However, the vaccination
114 records did not specify the range of symptoms but rather classified the infection as either
115 symptomatic or asymptomatic.

116 The full data were extracted from the hospital records on 15th June 2021. To avoid
117 misclassification of exposure, HCWs with missing vaccination information (e.g., no vaccination
118 date or vaccination type) or missing PCR testing information were excluded from the study.
119 Furthermore, the analysis excluded 24 HCWs who had a documented SARS-CoV-2 PCR-

120 confirmed infection prior to the study's starting date and additional 403 HCWs who had missing
121 or incomplete vaccination data or symptom data were also excluded. Hence, a total of 3246
122 HCWs eligible for this study.

123 **2.3. Outcomes**

124 The primary outcome for vaccine effectiveness analysis was the SARS-CoV-2 PCR-
125 confirmed infection among unvaccinated or vaccinated at any time during the study (i.e., during
126 the follow-up time) irrespective of symptom status. Infections were described as symptomatic if
127 their symptom status was seven days before or seven days of their PCR positive test date.

128 The primary outcome for the vaccine coverage analysis was the vaccination status (first
129 or second dose) by vaccine type. Healthcare workers vaccinated with ChAdOx1 had received
130 only one dose by the end of study period. This was due to the delay in ChAdOx1 vaccine
131 shipment to Kuwait that resulted in unavailability of the second dose for some HCWs who were
132 vaccinated in February and March (12-week waiting period between two doses). The ChAdOx1
133 shipment arrived to Kuwait on 13th June 2021; however, none of HCWs in this study received
134 the second dose by 15th June 2021.

135 **2.4. Person-time at risk**

136 The follow-up of all HCWs started on 24 December 2020, the day vaccine roll-out started
137 in Kuwait. All HCWs had at least one day of follow-up as unvaccinated. For each HCW, the
138 follow-up time (person-time at risk) ended at the earliest of the following events: occurrence of
139 an outcome event (SARS-CoV-2 PCR-confirmed infection), vaccination (for unvaccinated), or
140 end of study period.

141 **2.5. Data analysis**

142 Data were stratified by sociodemographic and occupation factors (i.e., covariates). These
143 were: age group (20 -30, 31- 40, 41 – 50, and >50), sex (male or female), nationality (Kuwaiti
144 national and non-Kuwaiti resident), staff group (Administrative or Executive; Nursing or Health-
145 care assistant; Doctor; Specialist Staff; Estates, Porters, or Security; and Pharmacist) and
146 occupation settings (categorized into six groups: 1) office or laboratory, 2) hospital pharmacy, 3)
147 outpatient including radiology, day ward, general practice, or renal dialysis unit, 4) inpatient
148 ward, theatres, emergency department, maternity unit or labor ward, or ambulance, 5) intensive
149 care, and 6) other (e.g., plaster and observational rooms).

150 For vaccine coverage analysis, we cross-tabulated three vaccination statuses as
151 unvaccinated; vaccinated with one ChAdOx1 dose; and vaccinated with one or two doses of
152 BNT162b2 with the study covariates. The relationship between vaccine coverage status and
153 covariates were assessed via chi-square statistic using STATA software version 16.1 (College
154 Station, Texas, USA). Furthermore, we also cross-tabulated SARS-CoV-2 PCR-confirmed
155 infection by vaccination status and each level of the covariates. Similarly, chi-square statistic
156 was used to assess relationships.

157 We used retrospective cohort study design to estimate the vaccine effectiveness in HCWs
158 population after the first and second dose. For the purpose of vaccine effectiveness analysis, the
159 HCWs were defined as unvaccinated (if they had not received any doses of either vaccine), fully
160 vaccinated (if at least 14 days had passed since receiving the second dose of BNT162b2), and
161 partial vaccination (if at least 28 days passed since receiving ChAdOx1 first dose or at least 14
162 days after receiving BNT162b2 first dose but before receiving second dose). The BNT162b2 13
163 person-days between receiving vaccine first dose and partial or full vaccination were considered
164 excluded from the analysis as at-risk person-time because immunity was considered

165 indeterminate. Similarly, the ChAdOx1 27 person-days after receiving vaccine first dose were
166 excluded. Therefore, incidence rates were calculated for: unvaccinated, ≥ 28 days after receiving
167 ChAdOx1 first dose, ≥ 14 days after receiving BNT162b2 first dose through receipt of second
168 dose, and ≥ 14 days after BNT162b2 second dose. Hazard ratios were estimated using Cox
169 proportional hazards model while accounting for time-varying vaccination status (i.e., receiving
170 first and second dose) as described elsewhere (Zhang, Reinikainen, Adeleke, Pieterse, &
171 Groothuis-Oudshoorn, 2018). Hazard ratios of partial vaccination person-days (≥ 28 days after
172 receiving ChAdOx1 first dose; ≥ 14 days after receiving BNT162b2 first dose and before second
173 dose) and to full vaccination person-days (≥ 14 days after BNT162b2 second dose) were
174 calculated and compared to that in unvaccinated person-days. Vaccine effectiveness was
175 calculated as $100\% \times (1 - \text{hazard ratio})$. An adjusted vaccine effectiveness model included the
176 covariates individually (i.e., univariate models) and those were significant at $P < 0.1$ were
177 included in the multivariate model. All analyses were conducted in STATA statistical software.

178

179 **3. Results**

180 There were 3246 HCWs that met the inclusion criteria and included in the analysis. The
181 median age of HCWs was 38 years (IQR = 33 - 44). Most of HCWs were females (63.4%), aged
182 31-40 (46.8%), non-Kuwaiti (82.3%), and worked in inpatient wards or ambulance settings
183 (47.3%) as shown in Table 1. Furthermore, 61.2% of HCWs were nursing or health-care assistant
184 staff.

185 Overall, 82.1% of HCWs received at least one vaccine dose while 17.9% of HCWs
186 remained unvaccinated by the end of the study. Interestingly, about half of the HCWs (50.4%)
187 received only one dose of ChAdOx1 vaccine; whereas 3.3% received one dose of BNT162b2

188 vaccine and 28.3% received two doses of BNT162b2 vaccine. Those who received only one dose
189 of BNT162b2 (3.3%) did not received their second dose because they were SARS-CoV-2
190 infected after the first dose (only two HCWs) or the study ended before they received it.

191 The percentage of HCWs classified as partially vaccinated (i.e., ≥ 28 days after receiving
192 one dose of ChAdOx1 or ≥ 14 days after receiving BNT162b2 first dose through receipt of
193 second dose) was 50.2% and 2.8%, respectively. However, the percentage of HCWs classified
194 as fully vaccinated (≥ 14 days after BNT162b2 second dose) was 28.2%.

195 The characteristics of unvaccinated and vaccinated HCWs by the two types of vaccine
196 are shown in Table 1. Twenty percent of females were unvaccinated compared to 10.6% of
197 males ($P < 0.001$). For age groups, 28.2% of HCWs aged 20-30 were unvaccinated, significantly
198 higher than other age groups ($P < 0.001$); whereas, within those received one or two doses of
199 BNT162b2 vaccine, the percentage of vaccinated HCWs in age groups (20 – 30 and > 50) was
200 higher than that in other age groups ($P < 0.001$). Interestingly, the percentages of unvaccinated
201 Kuwaitis (20.7%) and non-Kuwaitis (17.3%) HCWs were not significantly different ($P = 0.054$);
202 however, within those received one or two doses of BNT162b2, 60.7% of Kuwaiti HCWs were
203 vaccinated compared to 25.8% for non-Kuwaitis ($P < 0.001$). Among the different occupation
204 settings, 23.3% of HCWs who worked in office or laboratories were unvaccinated, significantly
205 higher compared to the remaining settings ($P < 0.001$) except for ‘other’. As for the HCW staff
206 groups, 31.5% of administrative or executive staff were unvaccinated, significantly higher than
207 other groups ($P < 0.001$). In addition, 58.4% of doctors received one or two doses of BNT162b2
208 vaccine significantly higher than other staff groups ($P < 0.001$).

209

210 SARS-CoV-2 PCR-confirmed infection prevalence with reported symptoms was 7.3%
211 (237/3246) during the study period. There were two additional SARS-CoV-2 PCR-confirmed
212 HCW infections with missing symptomatic status; hence, they were excluded from the analysis.
213 Therefore, all the 237 SARS-CoV-2 PCR-confirmed infection were classified as symptomatic.
214 As shown in Table 2, the infection prevalence was significantly higher among unvaccinated
215 female HCWs (20.8%) compared to 7.1% in those vaccinated with ChAdOx1 and 1.96% in those
216 vaccinated with one or two doses of BNT162b2. Similar findings were observed among male
217 HCWs. SARS-CoV-2 PCR-confirmed prevalence in the different age-groups and by nationality
218 were significantly higher in unvaccinated compared to the vaccinated groups. Furthermore, the
219 infection prevalence was significantly higher across the unvaccinated occupation settings
220 compared to those in vaccinated occupation settings except for “other” where the differences
221 were not significant ($P = 0.508$). The infection prevalence in staff groups were also significantly
222 higher in unvaccinated compared to vaccinated except for pharmacists ($P = 0.866$) (Table 2).

223

224 There were 114 SARS-CoV-2 infection during the 90,484 person-days of follow-up in
225 the unvaccinated group, an incidence rate of 126 per 100,000 person-days (Table 3). In the
226 partially vaccinated group, ≥ 28 days after ChAdOx1 first dose, there were 87 infections
227 (incidence rate of 31.4 per 100,000 person-days). Moreover, in the partially vaccinated group (\geq
228 14 days after receiving BNT162b2 vaccine through receipt of second dose), there were two
229 infections (incidence rate of 10.9 per 100,000 person-days). In the fully vaccinated group (≥ 14
230 days after BNT162b2 second dose) there were 10 infections (incidence rate of 6.3 per 100,000
231 person-days).

232

233 The estimated adjusted vaccine effectiveness of fully vaccinated was 94.5% (95%
234 confidence interval [CI] = 89.4%–97.2%). The vaccine effectiveness of partially vaccinated for
235 ChAdOx1 (≥ 28 days after one dose) was 75.4% (95% CI = 67.2%–81.6%) and for one dose
236 BNT162b2 (≥ 14 days through receipt of second dose) was 91.4% (95% CI = 65.1%–97.9%)
237 (Table 3). The individual covariates (sex, age group, nationality, occupation setting, staff group)
238 were significant predictors; hence, included in the multivariate model. However, these covariates
239 were not significant ($P > 0.05$) in the adjusted vaccine effectiveness multivariate model. We kept
240 the sociodemographic variables (sex, age group, and nationality) in the adjusted model and
241 compared the change between unadjusted and adjusted models. The change in vaccine
242 effectiveness point estimates were $<1\%$ between unadjusted and adjusted model.

243

244 **4. Discussion**

245

246 This retrospective cohort study was conducted between 24 December 2020 and 15 June
247 2021 (i.e., 173 days) at a secondary hospital in Kuwait shows that full vaccination (i.e.,
248 immunization) via BNT162b2 is highly effective against symptomatic COVID-19 among this
249 HCW population. Furthermore, ChAdOx1 one dose was relatively effective (Table 3).

250 Vaccine coverage with at least one dose among HCWs after 173 days (about 5.8 months)
251 was 82.1% of HCWs including 28.3% who received two doses. However, still there were 17.9%
252 of HCWs unvaccinated by the end of the study which is a concern. Healthcare workers have
253 been given the priority for vaccination in Kuwait as most countries; therefore, efforts are needed
254 to better understand reasons for vaccine hesitancy in this high-risk exposure group. Other studies
255 have reported that most HCWs were vaccinated with at least one dose within two to three months

256 of vaccine roll-out (i.e., 90% in UK; 79% in Israel; and 75% in USA) (Amit et al., 2021; Hall et
257 al., 2021; Thompson et al., 2021).

258 There were significant differences in vaccine coverage by demographics, occupation
259 setting, and staff group. Similar differences by factors such as age, sex, ethnicity, and occupation
260 have been reported in other studies (Curtis et al., 2021; Galanis, Vraka, Fragkou, Bilali, &
261 Kaitelidou, 2020; Martin et al., 2021). The differences in vaccine coverage we reported among
262 this population highlights the importance of equitable vaccination program to all HCWs in
263 Kuwait.

264 Vaccine effectiveness of full vaccination with two doses of BNT162b2 vaccine was
265 94.5% (95% CI = 89.4%–97.2%) against symptomatic PCR-confirmed SARS-CoV-2 infection,
266 whereas it was 75.4% (95% CI = 67.2%–81.6%) for ChAdOx1 single dose. These findings are
267 consistent with those from other population-level studies that estimated vaccine effectiveness
268 against SARS-CoV-2 infection (symptomatic and/or asymptomatic) among HCWs (Amit et al.,
269 2021; Hall et al., 2021; Moustsen-Helms et al., 2021; Thompson et al., 2021) and those from
270 vaccine phase III trials (Knoll & Wonodi, 2021; Polack et al., 2020). For instance, in a study
271 from the US CDC, the authors reported that vaccine effectiveness against SARS-CoV-2 infection
272 among HCWs with full immunization (≥ 14 days after BNT162b2 second dose) was 90% (95%
273 CI = 68% – 97%) (Thompson et al., 2021). In other studies on HCWs, BNT162b2 vaccine
274 effectiveness against SARS-CoV-2 infection (≥ 7 day post second dose) was 85% (95% CI =
275 74% – 96%) in the UK (Hall et al., 2021), and it was 85% (95% CI = 71% - 92%) 15 – 24 days
276 after second dose in Israel (Amit et al., 2021). The main difference between these studies and
277 ours is that HCWs were regularly tested for SARS-CoV-2 infection (active surveillance) while in
278 our study it was based on reported of PCR-confirmed infection by HCWs to the hospital

279 management (passive surveillance). Nonetheless, it is mandatory for HCWs to report if they
280 were in close contact with a positive case or have tested positive via nasopharyngeal PCR.

281 Our findings highlight the effectiveness of vaccine in reducing the risk of symptomatic
282 infection among HCWs across sociodemographic factors (sex, age, and nationality) and across
283 occupation setting and staff group. Importantly, reducing infection rate among HCWs via
284 vaccination is critical to protect their health and lower the transmission risk to their contacts
285 (coworkers and patients) as well as to the public (Buitrago-Garcia et al., 2020).

286 The partial vaccination (≥ 28 days after ChAdOx1 one dose) provided about 75%
287 protection. This similar with to the Phase III trial results (Hyams et al.; Knoll & Wonodi, 2021).
288 However, to best of our knowledge, there is no estimate on vaccine effectiveness of ChAdOx1 in
289 a HCW population. Furthermore, partial vaccination (≥ 14 days after first dose but before second
290 dose) also provided high level of protection from infection in HCWs in this study; however, this
291 limited by the relatively short at-risk person-time. Recent studies showed that partial vaccination
292 among HCWs in the U.S. (≥ 21 days after BNT162b2 first dose) had vaccine effectiveness of
293 80% (95% CI = 59% – 90%) and 72% (95% CI = 58%–86%) in a study from UK (Hall et al.,
294 2021; Thompson et al., 2021). Both studies were based on regular SARS-CoV-2 testing program.
295 Moreover, a study from Israel reported 60% (95% CI = 38%–74%) one dose BNT162b2 vaccine
296 effectiveness against confirmed SARS-CoV-2 infection based on hospital records (passive
297 reporting) (Amit et al., 2021). It is worth mentioning that SARS-CoV-2 B.1.1.7 (Alpha) variant
298 was detected in Kuwait in January 2021 and could have been the dominant variant during the
299 study period; however, there are no available data in Kuwait to determine the percentage and
300 distribution of infections with this variant. Moreover, the B.1.617.2 (Delta) variant was reported

301 in Kuwait in late June 2021 (after the study ended); hence, it did not confound the effectiveness
302 results.

303 This study has several limitations. First, the study was based on one public secondary
304 hospital and might not be generalizable to HCWs in other public hospitals in Kuwait. However,
305 this hospital is one of the major healthcare facilities in Kuwait and serves over a quarter of the
306 country's population. Second, the identification of HCWs SARS-CoV-2 PCR-confirmed
307 infections was based on passive reporting to the hospital management due to lack of active
308 laboratory surveillance. However, it was/is required by all HCWs to report PCR-confirmed
309 infections to their upper management within each hospital's department. Furthermore,
310 underreporting PCR-confirmed infections might underestimate the 'actual' number of infections
311 regardless of vaccination status; if this disproportionately impacted those who were unvaccinated
312 compared to those who were vaccinated, this could overestimate vaccine effectiveness. Third,
313 vaccine effectiveness estimates for partial immunity (≥ 14 days after BNT162b2 first dose
314 through receipt of second dose) had wide confidence intervals which likely due to the low
315 number of PCR-confirmed infections reported.

316 In conclusion, vaccine effectiveness of both BNT162b2 and ChAdOx1 COVID-19
317 vaccines in HCW under 'real-world' conditions demonstrated that vaccine is effective in
318 preventing most symptomatic infection across age groups, nationalities, occupation setting, and
319 staff groups. A significant proportion (17.9%) of HCWs were unvaccinated despite the vaccine
320 accessibility. Efforts are needed to better understand reasons for HCW vaccine hesitancy.
321 Although vaccination is highly effective against infection, hospitalization, and mortality as
322 shown in other studies, it is important for HCWs to continue to exercise physical distancing,

- 323 wear personal protective equipment while in contact with patients, and follow other infection
- 324 control and prevention measures.

325 **5. References**

326

327 Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A. (2021). Effectiveness of the BNT162b2 Covid-19

328 Vaccine against the B.1.1.7 and B.1.351 Variants. *New England Journal of Medicine*.

329 doi:10.1056/NEJMc2104974

330 Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y., & Leshem, E. (2021). Early rate reductions of

331 SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. *The Lancet*,

332 397(10277), 875-877. doi:10.1016/S0140-6736(21)00448-7

333 Buitrago-Garcia, D., Egli-Gany, D., Counotte, M. J., Hossmann, S., Imeri, H., Ipekci, A. M., . . .

334 Low, N. (2020). Occurrence and transmission potential of asymptomatic and

335 presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.

336 *PLOS Medicine*, 17(9), e1003346. doi:10.1371/journal.pmed.1003346

337 Curtis, H. J., Inglesby, P., Morton, C. E., MacKenna, B., Walker, A. J., Morley, J., . . . Goldacre, B.

338 (2021). Trends and clinical characteristics of COVID-19 vaccine recipients: a federated

339 analysis of 57.9 million patients' primary care records in situ using OpenSAFELY.

340 *medRxiv*, 2021.2001.2025.21250356. doi:10.1101/2021.01.25.21250356

341 Galanis, P. A., Vraka, I., Fragkou, D., Bilali, A., & Kaitelidou, D. (2020). Intention of health care

342 workers to accept COVID-19 vaccination and related factors: a systematic review and

343 meta-analysis. *medRxiv*, 2020.2012.2008.20246041. doi:10.1101/2020.12.08.20246041

344 Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., . . . Alroy-Preis, S.

345 (2021). Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2

346 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide

347 vaccination campaign in Israel: an observational study using national surveillance data.
348 *The Lancet*, 397(10287), 1819-1829. doi:10.1016/S0140-6736(21)00947-8

349 Hall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., . . . Heeney, J. L. (2021).
350 COVID-19 vaccine coverage in health-care workers in England and effectiveness of
351 BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort
352 study. *The Lancet*, 397(10286), 1725-1735. doi:10.1016/S0140-6736(21)00790-X

353 Hyams, C., Marlow, R., Maseko, Z., King, J., Ward, L., Fox, K., . . . Finn, A. Effectiveness of
354 BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in
355 people aged at least 80 years: a test-negative, case-control study. *The Lancet Infectious*
356 *Diseases*. doi:10.1016/S1473-3099(21)00330-3

357 Knoll, M. D., & Wonodi, C. (2021). Oxford–AstraZeneca COVID-19 vaccine efficacy. *The Lancet*,
358 397(10269), 72-74. doi:10.1016/S0140-6736(20)32623-4

359 Martin, C. A., Marshall, C., Patel, P., Goss, C., Jenkins, D. R., Ellwood, C., . . . Pareek, M. (2021).
360 Association of demographic and occupational factors with SARS-CoV-2 vaccine uptake in
361 a multi-ethnic UK healthcare workforce: a rapid real-world analysis. *medRxiv*,
362 2021.2002.2011.21251548. doi:10.1101/2021.02.11.21251548

363 Moustsen-Helms, I. R., Emborg, H.-D., Nielsen, J., Nielsen, K. F., Krause, T. G., Mølbak, K., . . .
364 Valentiner-Branth, P. (2021). Vaccine effectiveness after 1st and
365 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care
366 facility residents and healthcare workers – a Danish cohort study. *medRxiv*,
367 2021.2003.2008.21252200. doi:10.1101/2021.03.08.21252200

- 368 Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., . . . Gruber, W. C.
369 (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England*
370 *Journal of Medicine*. doi:10.1056/NEJMoa2034577
- 371 Thompson, M., Burgess, J., Naleway, A., Tyner, H., Yoon, S., Meece, J., . . . Gaglani, M. (2021).
372 Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19
373 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First
374 Responders, and Other Essential and Frontline Workers — Eight U.S. Locations,
375 December 2020–March 2021. *MMWR. Morbidity and Mortality Weekly Report*, 70.
376 doi:10.15585/mmwr.mm7013e3
- 377 Vasileiou, E., Simpson, C. R., Robertson, C., Shi, T., Kerr, S., Agrawal, U., . . . Sheikh, A. (2021).
378 Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in
379 Scotland: National Prospective Cohort Study of 5.4 Million People. Available at
380 <http://dx.doi.org/10.2139/ssrn.3789264>.
- 381 Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., . . .
382 Zuidewind, P. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)
383 against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,
384 South Africa, and the UK. *The Lancet*, 397(10269), 99-111. doi:10.1016/S0140-
385 6736(20)32661-1
- 386 Zhang, Z., Reinikainen, J., Adeleke, K. A., Pieterse, M. E., & Groothuis-Oudshoorn, C. G. M.
387 (2018). Time-varying covariates and coefficients in Cox regression models. *Annals of*
388 *translational medicine*, 6(7), 121-121. doi:10.21037/atm.2018.02.12
389

390 **Table 1:** Characteristics of vaccinated and unvaccinated HCWs (n=3246) and factors associated with ChAdOx1 or BNT162b2 coverage at a major secondary
 391 hospital in Kuwait, December 24, 2020–June 15, 2021

Characteristics		Total No.	Unvaccinated (row %)	Vaccinated with one dose only (ChAdOx1) (row %)	Vaccinated with one or two doses (BNT162b2) ^a (row %)
Sex	Female	2075	20.0	50.9	27.1
	Male	1171	10.6	48.8	40.7
<i>P-value</i> ^b			<0.001	0.267	<0.001
Age groups	20 - 30	443	28.2	30.9	40.9
	31 - 40	1518	19.7	55.0	25.3
	41 - 50	869	12.5	55.6	31.9
	> 50	416	11.3	41.6	47.1
<i>P-value</i>			<0.001	<0.001	<0.001
Nationality	Kuwaiti	575	20.7	18.6	60.7
	Non-Kuwaiti	2671	17.3	56.9	25.8
<i>P-value</i>			0.054	<0.001	<0.001
Occupation setting ^c	Offices and laboratory (lower risk)	446	23.3	36.8	39.9
	Patient facing non-clinical	170	15.3	47.1	37.7
	Outpatient	618	16.7	45.5	37.9
	Inpatient wards and ambulance	1536	18.4	53.4	28.2
	Intensive Care (Higher risk)	407	11.6	58.2	30.2
	Other	69	24.6	66.7	8.7
<i>P-value</i>			<0.001	<0.001	<0.001
Staff group	Administrative or executive	54	31.5	24.1	44.4
	Nursing or health-care assistant	1985	17.4	59.5	23.1
	Doctor	541	11.5	30.1	58.4
	Specialist Staff	569	24.1	40.8	35.2
	Estates, porters, or security	15	0	100	0
	Pharmacist	82	22	29.3	48.8
<i>P-value</i>			<0.001	<0.001	<0.001
Total (%)		3246	581 (17.9)	1636 (50.4)	1029 (31.7)

392

393 ^a Total vaccinated includes 108 HCWs who received one BNT162b2 vaccine dose and 921 who received two BNT162b2 vaccine doses

394

395 ^b P-values (comparing the column percentages of vaccinate status by sociodemographic, occupation setting, and staff group categories were calculated using
396 Pearson's chi-square test (cells with ≥ 5 observations) or Fisher's exact test (cells with < 5 observations) in STATA statistical software.

397 ^c Occupation setting categories were: 1: office or laboratory; 2: Hospital pharmacy, 3: outpatient including radiology, day ward, general practice, or renal dialysis
398 unit; 4: inpatient ward, theatres, emergency department, maternity unit or labor ward, or ambulance; 5: intensive care; and 6: other (e.g., plaster and observational
399 rooms).

400

401 **Table 2:** Prevalence of SARS-CoV-2 PCR–confirmed infections in HCWs (n=3246) received BNT162b2 or ChAdOx1 COVID-19 vaccines at a major secondary
 402 hospital in Kuwait, December 24, 2020–June 15, 2021

Characteristics	Categories	No. Unvaccinated (Infection %)	Vaccinated with one dose only (ChAdOx1) n (Infection %)	Vaccinated with one or two doses (BNT162b2) n (Infection %) ^a	P-value ^b
Sex	Female	456 (20.8)	1057 (7.1)	562 (2.0)	<0.001
	Male	124 (15.3)	571 (4.9)	476 (1.9)	<0.001
Age groups	20 - 30	125 (21.6)	137 (9.5)	181 (2.8)	<0.001
	31 - 40	299 (16.7)	835 (6.6)	384 (0.8)	<0.001
	41 - 50	109 (25.7)	483 (6.0)	277 (2.2)	<0.001
	> 50	47 (19.2)	173 (3.5)	196 (3.1)	<0.001
Nationality	Kuwaiti	119 (16.8)	107 (7.5)	349 (2.0)	<0.001
	Non-Kuwaiti	461 (20.4)	1521 (6.3)	689 (1.9)	<0.001
Occupation setting ^c	Offices and laboratory (lower risk)	104 (26.9)	164 (9.2)	178 (2.8)	<0.001
	Patient facing non-clinical	26 (19.2)	80 (5.0)	64 (3.1)	<0.001
	Outpatient	103 (12.6)	281 (3.2)	234 (2.1)	<0.001
	Inpatient wards and ambulance	283 (19.8)	820 (6.5)	433 (0.9)	<0.001
	Intensive Care (Higher risk)	47 (21.3)	237 (7.2)	123 (3.3)	<0.001

	Other	17 (11.8)	46 (10.9)	6 0.0	0.508
	Administrative or executive	17 (23.5)	13 (15.4)	24 (4.2)	<0.001
	Nursing or health-care assistant	346 (20.5)	1181 (6.4)	458 (1.3)	<0.001
	Doctor	62 (19.4)	163 (5.5)	316 (1.9)	<0.001
Staff group	Specialist Staff	137 (19.0)	232 (6.5)	200 (2.5)	<0.001
	Estates, porters, or security	0 0.0	15 0.0	0 0.0	-
	Pharmacist	18 (5.6)	24 (8.3)	40 (6.1)	0.866

403

404 ^a Total vaccinated includes 108 HCWs who received one BNT162b2 vaccine dose and 921 who received two BNT162b2 vaccine doses

405 ^b P-values (comparing the row percentages of vaccinate status by sociodemographic, occupation setting, and staff group categories were calculated using

406 Pearson's chi-square test (cells with ≥ 5 observations) or Fisher's exact test (cells with < 5 observations) in STATA statistical software. “ – “ because of lack of
407 enough data for chi-square statistic to test relationship.

408 ^c Occupation setting categories were: 1: office or laboratory; 2: Hospital pharmacy, 3: outpatient including radiology, day ward, general practice, or renal dialysis
409 unit; 4: inpatient ward, theatres, emergency department, maternity unit or labor ward, or ambulance; 5: intensive care; and 6: other.

410

411 **Table 3.** Effectiveness of ChAdOx1 and BNT162b2 COVID-19 vaccines against SARS-CoV-2 symptomatic infection among HCWs (n= 3246) at a major
 412 secondary hospital in Kuwait, December 24, 2020–June 15, 2021

COVID-19 vaccination status	Total person time (days)	Number of PCR positives	Incidence rate per 100,000 person-days	Unadjusted vaccine effectiveness % (95% CI) ^a	Adjusted vaccine effectiveness % (95% CI) ^{a, b}
Unvaccinated	90,367	114	126.2	Reference	Reference
Partially vaccinated					
≥ 28 days after receiving ChAdOx1 first dose only ^c	159,423	87	54.6	75.5 (67.6 - 81.5)	75.4 (67.2 - 81.6)
≥ 14 days after receiving BNT162b2 first dose through receipt of second dose	7,196	2	27.8	91.6 (65.9 - 97.9)	91.4 (65.1 - 97.9)
Fully vaccinated					
≥ 7 days after BNT162b2 second dose	90,015	12	13.3	95.1 (90.6 - 97.4)	94.5 (89.4 - 97.2)

413

414 ^a Vaccine effectiveness was estimated using a Cox proportional hazards model accounting for time-varying immunization status in STATA statistical software.

415 ^b Hazard ratio is adjusted for age, sex, and nationality

416 ^c Participants received first dose of ChAdOx1 but had not received second dose by the end of the study period.